Abstract:Major depressive disorder (MDD) is a worldwide concern owing to its negative impact on the quality of life. Gamma-aminobutyric acid (GABA), an essential neurotransmitter in the brain, is important for regulating the enteric nervous system and gut-brain dual communication (gut-brain axis), thus providing gastrointestinal GABA and GABA-related pathways with possible targets for MDD treatment. However, the use of GABA for this disease remains limited due to its poor pharmacokinetic properties, including the low permeability through the blood-brain barrier, and the rapid clearance from the gastrointestinal tract. Since poly(amino acid)s are advantageous for improving the beneficial bioactivities of conventional amino acids, poly(gamma-aminobutyric acid) (poly(GABA)) is a potential candidate for MDD therapy. Nevertheless, the non-water-soluble and non-dispersible characteristics of poly(GABA) render difficulty in administering its conventional forms in vitro/in vivo, thereby hindering its therapeutic applications. Therefore, this study proposes a new design for poly(GABA) in nanoparticle form, which is composed of the amphiphilic diblock copolymers of poly(GABA) and poly(ethylene glycol), providing a suitable formulation for medication applications. Herein, we report on a new orally deliverable poly(GABA)-based nanoparticles (NanoGABA) in aqueous media and their efficacy on mouse depression models. NanoGABA treatment efficiently attenuated depression-like symptoms as evidenced by behavioral tests (forced swimming tests and tail suspension tests) and stress biomarkers (corticosterone). These findings suggest that the newly designed poly(GABA)-based nanoparticles are a promising candidate for the treatment of depression. STATEMENT OF SIGNIFICANCE: This research is the first to report the preparation of poly(GABA)-based nanoparticles in aqueous conditions with beneficial physical properties to open the gate for medical and pharmaceutical applications of poly (GABA). It is also a pioneer in using poly(GABA)-based materials for major depressive disorder therapeutics in vivo. Oral administration of NanoGABA attenuates depressive-like symptoms by targeting the enteric nervous system possibly through modulation of the gut-brain axis pathways with negligible toxicity, suggesting that NanoGABA is a promising therapeutic agent for major depressive disorders.

Borneol-modified PEGylated Graphene Oxide As a Nanocarrier for Brain-Targeted Delivery of Ginsenoside Rg1 Against Depression.

Surface Modification of PGP for a Neutrophil-Nanoparticle Co-Vehicle to Enhance the Anti-Depressant Effect of Baicalein.

Brain‐Targeted Black Phosphorus‐Based Nanotherapeutic Platform for Enhanced Hypericin Delivery in Depression

Transferrin-modified Carboxymethyl Chitosan-Chitosan Nanoparticles As an Efficient Delivery Carrier for Targeted Therapy of Depression

ROS-Targeted Depression Therapy via BSA-Incubated Ceria Nanoclusters

Stimuli-responsive nanoparticles delivered by a nasal-brain pathway alleviate depression-like behavior through extensively scavenging ROS

Cell-liposome Delivery System Based on Neuroinflammation to Target the Amygdala for Ameliorating Depressive-Like Behaviors

Ginsenoside Rg1: A Neuroprotective Natural Dammarane‐Type Triterpenoid Saponin With Anti‐Depressive Properties

Combining Network Pharmacology and Transcriptomic Strategies to Explore the Pharmacological Mechanism of Total Ginsenoside Ginseng Root and Its Impact on Antidepressant Effects

Targeted graphene oxide for drug delivery as a therapeutic nanoplatform against Parkinson's disease

Nanocarrier drug delivery system: promising platform for targeted depression therapy

Enhanced antidepressant effects of BDNF-quercetin alginate nanogels for depression therapy

Intranasal co-delivery of berberine and evodiamine by self-assembled thermosensitive in-situ hydrogels for improving depressive disorder

Ginsenoside Rg1 in neurological diseases: From bench to bedside

Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders

Advances in Nano-Enabled Platforms for the Treatment of Depression

Alginate nanogels-based thermosensitive hydrogel to improve antidepressant-like effects of albiflorin via intranasal delivery

Cerium Oxide-Modified Pd Nanosheets Encapsulated by Red Blood Cell Membranes for High-Efficiency RONS Scavenging in Depression Treatment.

Ginsenoside Rg1 Reduced Microglial Activation and Mitochondrial Dysfunction to Alleviate Depression-Like Behaviour Via the GAS5/EZH2/SOCS3/NRF2 Axis

Trash to treasure: A human beard derived photothermal drug delivery platform for depression therapy

MRI-Guided Focused Ultrasound-Induced Blood Brain Barrier Disruption to Deliver Glial Cell Line Derived Neurotropic Factor Proteins into Brain to Treat Rat Depression